Affimed  (Germany) developer of recombinant antibody therapeutics had a second closing of an additional $7.8M Series B financing from Novo Nordisk bringing the total round to $47.2M. Earlier participants include BioMedInvest, OrbiMed Advisors, Life Sciences Partners and FirstVentury.